Results 231 to 240 of about 61,480 (319)
Application of Physiologically-Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4-Mediated Pirtobrutinib-Drug Interactions. [PDF]
Tian DD, Hall SD, Chapman SC, Posada MM.
europepmc +1 more source
Opportunities of patient‐derived organoids in drug development
Various model systems are utilised during drug development starting from basic research, moving to preclinical research and development for clinical applications in order to identify new drugs to improve human health. However, there are characteristics of humans that are not captured by established models.
Antonia Büning, Elena Reckzeh
wiley +1 more source
Concurrent Administration of Triazoles with Chemotherapeutic and/or Immunosuppressant Agents Known to Have Moderate-to-Severe Drug-Drug Interactions in Patients with Hematologic Malignancies Hospitalized for Invasive Aspergillosis. [PDF]
Walsh TJ +4 more
europepmc +1 more source
ABSTRACT Intrinsic factors such as age and ethnicity influence statin pharmacokinetics (PK) and may increase the risk of muscle‐related adverse events. This study investigated the effect of age on the PK of simvastatin (SV) and its active metabolite, simvastatin acid (SVA), in healthy Thai subjects using an LC–MS/MS assay while accounting for key ...
Thanate Srimatimanon +11 more
wiley +1 more source
Investigating the therapeutic mechanism of Asarum for oral ulcer from a network pharmacology perspective. [PDF]
Zhu X, Zhao M, Zhu H, Wang Y, Lu Y.
europepmc +1 more source
C. Awortwe +7 more
semanticscholar +1 more source
ABSTRACT Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy ...
Andy Sykes +15 more
wiley +1 more source

